Literature DB >> 20081815

Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Sungwook Choi1, Stephen Connelly, Natàlia Reixach, Ian A Wilson, Jeffery W Kelly.   

Abstract

A small molecule that could bind selectively to and then react chemoselectively with a non-enzyme protein in a complex biological fluid, such as blood, could have numerous practical applications. Herein, we report a family of designed stilbenes that selectively and covalently modify the prominent plasma protein transthyretin in preference to more than 4,000 other human plasma proteins. They react chemoselectively with only one of eight lysine e-amino groups within transthyretin. The crystal structure confirms the expected binding orientation of the stilbene substructure and the anticipated conjugating amide bond. These covalent transthyretin kinetic stabilizers exhibit superior amyloid inhibition potency compared to their noncovalent counterparts, and they prevent cytotoxicity associated with amyloidogenesis. Though there are a few prodrugs that, upon metabolic activation, react with a cysteine residue inactivating a specific non-enzyme, we are unaware of designed small molecules that react with one lysine e-amine within a specific non-enzyme protein in a complex biological fluid.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20081815      PMCID: PMC3107129          DOI: 10.1038/nchembio.281

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  48 in total

1.  Identification and biological activity of the active metabolite of clopidogrel.

Authors:  P Savi; J M Pereillo; M F Uzabiaga; J Combalbert; C Picard; J P Maffrand; M Pascal; J M Herbert
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

2.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.

Authors:  X Jiang; C S Smith; H M Petrassi; P Hammarström; J T White; J C Sacchettini; J W Kelly
Journal:  Biochemistry       Date:  2001-09-25       Impact factor: 3.162

3.  Rational design of potent human transthyretin amyloid disease inhibitors.

Authors:  T Klabunde; H M Petrassi; V B Oza; P Raman; J W Kelly; J C Sacchettini
Journal:  Nat Struct Biol       Date:  2000-04

4.  Structure of rat transthyretin (rTTR) complex with thyroxine at 2.5 A resolution: first non-biased insight into thyroxine binding reveals different hormone orientation in two binding sites.

Authors:  A Wojtczak; V Cody; J R Luft; W Pangborn
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2001-07-23

5.  Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.

Authors:  J O'Brien; I Wilson; T Orton; F Pognan
Journal:  Eur J Biochem       Date:  2000-09

6.  Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.

Authors:  P Hammarström; X Jiang; S Deechongkit; J W Kelly
Journal:  Biochemistry       Date:  2001-09-25       Impact factor: 3.162

7.  The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.

Authors:  H A Lashuel; C Wurth; L Woo; J W Kelly
Journal:  Biochemistry       Date:  1999-10-12       Impact factor: 3.162

8.  A glimpse of a possible amyloidogenic intermediate of transthyretin.

Authors:  K Liu; H S Cho; H A Lashuel; J W Kelly; D E Wemmer
Journal:  Nat Struct Biol       Date:  2000-09

9.  Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid.

Authors:  P W Baures; V B Oza; S A Peterson; J W Kelly
Journal:  Bioorg Med Chem       Date:  1999-07       Impact factor: 3.641

10.  Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.

Authors:  H E Purkey; M I Dorrell; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

View more
  31 in total

1.  A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.

Authors:  Sungwook Choi; Derrick Sek Tong Ong; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-10-21       Impact factor: 15.419

2.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

Review 3.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 4.  Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.

Authors:  Susan L Lindquist; Jeffery W Kelly
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-12-01       Impact factor: 10.005

5.  Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.

Authors:  Neil P Grimster; Stephen Connelly; Aleksandra Baranczak; Jiajia Dong; Larissa B Krasnova; K Barry Sharpless; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-02-14       Impact factor: 15.419

6.  Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans.

Authors:  Kayalvizhi Madhivanan; Erin R Greiner; Miguel Alves-Ferreira; David Soriano-Castell; Nirvan Rouzbeh; Carlos A Aguirre; Johan F Paulsson; Justin Chapman; Xin Jiang; Felicia K Ooi; Carolina Lemos; Andrew Dillin; Veena Prahlad; Jeffery W Kelly; Sandra E Encalada
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

Review 7.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

8.  Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain.

Authors:  Gizem Akçay; Matthew A Belmonte; Brian Aquila; Claudio Chuaqui; Alexander W Hird; Michelle L Lamb; Philip B Rawlins; Nancy Su; Sharon Tentarelli; Neil P Grimster; Qibin Su
Journal:  Nat Chem Biol       Date:  2016-09-05       Impact factor: 15.040

Review 9.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

10.  Peptide-Based Inhibitors of Fimbrial Biogenesis in Porphyromonas gingivalis.

Authors:  Sarah R Alaei; Jin Ho Park; Stephen G Walker; David G Thanassi
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.